Hamilton ETFs Announces Name Changes for HEB and MIX

TORONTO--(BUSINESS WIRE)-- Hamilton Capital Partners Inc. (“Hamilton ETFs”) announces that effective April 30, 2026, the legal names of the ETFs listed in the following table (the “Name Changes”) were changed. There were no changes to the investment objectives, investment strategies or management of the ETFs associated with these name changes.

It is anticipated that the Name Changes will be reflected on the Toronto Stock Exchange (the “TSX”) at the open of the market on May 11, 2026.

There will be no change to the ticker symbols (TSX: HEB and TSX: MIX) or CUSIP numbers for the ETFs associated with the Name Changes.

The investment objectives and strategies of the ETFs, as outlined in their prospectus, are available on SEDAR+ (www.sedarplus.ca) or the company’s website (www.hamiltonetfs.com) and remain unchanged.

About Hamilton Capital Partners Inc. (Hamilton ETFs)
With over $15 billion in assets under management, Hamilton ETFs is one of Canada’s fastest growing ETF providers, offering a suite of innovative exchange traded funds (ETFs) designed to maximize income and growth from trusted sectors in Canada and across the globe. The firm is also an active commentator on the global financial services sector and Canadian banks; the firm’s most recent Insights can be found at www.hamiltonetfs.com/insights-commentary.

Commissions, management fees and expenses all may be associated with an investment in exchange traded funds (ETFs). Please read the prospectus before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260504413936/en/

For investor inquiries: Contact Hamilton ETFs at (416) 941-9888, [email protected]

For media inquiries: Contact Louis Ribieras, Head of Marketing, (416) 941-9996, [email protected]

Source: Hamilton Capital Partners Inc.

You May Also Be Interested In

• TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
• Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026
• Prime Drink Group Announces Private Placement and Agreed Resolution with Creditors